Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 22, 2010

View Archived Issues

Oncolytic vaccinia virus GL-ONC1 well tolerated in patients with solid cancers

Phase II trials assess Amgen's antibodies in pancreatic and non-small cell lung cancer

Continued benefit seen with 4-year odanacatib therapy in postmenopausal women

DHOdehase inhibitor LAS-186323 shows favorable safety and pharmacokinetics

Scientists identify potential biomarkers of delirium in ICU patients

FDA approves subcutaneous administration of Gamunex-C in primary immunodeficiency

Cytheris begins phase II EraMune 01 trial of CYT-107 in HIV-infected patients

BioMarin Pharma launches program for BMN-111 in the treatment of achondroplasia

Takeda submits azilsartan medoxomil MAA for essential hypertension

Agensys and Seattle Genetics begin phase I trial of ASG-5ME in prostate cancer

Pearl Therapeutics raises funds for phase II PT-003 program

Sigma-Tau describes new inhibitors of fatty acid amide hydrolase

Transcept Pharma presents preliminary data from Intermezzo driving study

Diamyd reports data from 4-week observation period in phase I NP-2 trial

Bristol-Myers Squibb claims new inhibitors of gamma-secretase

Intercell and Romark to begin phase II trial of IC-41/nitazoxanide combination in hepatitis C

Protege phase III trial of teplizumab does not meet primary efficacy endpoint

New anticancer agents identified by sanofi-aventis

Gruenenthal presents new bradykinin B1 receptor antagonists

Shionogi-ViiV Healthcare begins phase III program for HIV integrase inhibitor

Photocure enters into agreement with Salix Pharma for photodynamic colorectal diagnostic

EMA initiates review of Orion's centralized MAA for dexmedetomidine

Cytos Biotechnology collaborates with NIH and SAIC for malaria vaccines

Helix BioPharma reports data from phase II topical interferon alfa-2b trial

Phase I results reported for APD-916 in narcolepsy with cataplexy

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...